By:  Greg Maguire, Ph.D.

Background: Stem cell therapy has been shown to be highly effective in the laboratory setting.
In the lab setting, studies show that in many instances the therapeutic effects of stem cells is solely because of SRM.  Translation of stem cell therapeutics from lab to clinic is often unsuccessful.

Question: Why not use the stem cells themselves for therapeutic – they provide a vehicle for making and delivering SRM?

1.) Because of the cost and difficulty of handling live cells, shipping, then the subsequent handling at the clinic.
2.) Because many cells are lost at time of injection. For example, 109 cardiomyocytes are needed to repair experimental myocardial infarcts. Many cells don’t survive injection, and many are rapidly lost after injection.

Instead: BRS controls the stem cells in the lab, collects the molecules responsible for repairing the tissue, and doses the molecules at the impaired tissue in a defined dosing schedule.
Our methodology extends well beyond our topical products where, for example, eye drops for cataract can be dosed to the eye, and future S²RM therapeutics can be injected into the eye for diseases of retinal degeneration.

Using S²RM therefore, assures delivery of the healing molecules to the patient, unlike the case when cells are injected into the patient where the SRM from the cells may not even be delivered.

Bottom Line: Cell therapies may not translate well from lab to clinic for the above reasons, but the S²RM therapeutics have proven themselves in the clinical setting for a number of indications.